Literature DB >> 7251192

Adjuvant effect of nonionic block polymer surfactants in humoral and cellular immunity.

H Snippe, M J De Reuver, F Strickland, J M Willers, R L Hunter.   

Abstract

The adjuvant activities of four chemically similar, but physicochemically different nonionic surface-active agents called pluronic polyols F 68, L 31, L 101 and L 121 were studied. These four agents were tested in mice using an experimental model developed for studying the adjuvant activity of the cationic surface-active agent dimethyl dioctadecyl ammonium bromide (DDA). L 121 and DDA enhanced the primary antibody response to sheep red blood cells (SRBC) while F 68, L 31 and L 101 suppressed this response. The secondary humoral response to SRBC was enhanced by the polyol L 121 while the secondary response to dinitrophenylated bovine serum albumin (DNP22-BSA) was enhanced by both L 121 and L 101. DDA and the polyol L 101 were very effective adjuvants for induction of delayed-type hypersensitivity (DTH) to SRBC and DNP22-BSA after intracutaneous immunization of mice with a mixture of antigen and adjuvant. Since the four pluronic polyols were composed of identical chemical constituents, we proposed that difference in their activities as adjuvants were due to variation in their physicochemical properties. A correlation was found between a physicochemical parameter, the hydrophilelipophile balance (HLB), and the adjuvant activities of the pluronic polyols and several other types of nonionic surface-active agents. The agents which were strong adjuvants all had HLB values within a narrow range which classified them as spreading agents.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7251192     DOI: 10.1159/000232780

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  14 in total

1.  Nonionic block polymer surfactants enhance immunogenicity of pneumococcal hexasaccharide-protein vaccines.

Authors:  G J Zigterman; H Snippe; M Jansze; E B Ernste; M J De Reuver; J M Willers
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

2.  Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice.

Authors:  Neeta Jain-Gupta; Araceli Contreras-Rodriguez; Ramesh Vemulapalli; Sharon G Witonsky; Stephen M Boyle; Nammalwar Sriranganathan
Journal:  FEMS Immunol Med Microbiol       Date:  2012-12

3.  Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bioactivity of an emulsion vehicle.

Authors:  D M Lidgate; R C Fu; N E Byars; L C Foster; J S Fleitman
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

4.  Stimulation of liposome-induced humoral immune responses by non-ionic block polymer surfactants in Xid mice.

Authors:  G J Zigterman; M Jansze; H Snippe; J M Willers
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

5.  Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates.

Authors:  G J Zigterman; K Schotanus; E B Ernste; G J Van Dam; M Jansze; H Snippe; J M Willers
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

6.  Block copolymers have differing adjuvant effects on the primary immune response elicited by genetic immunization and on further induced allergy.

Authors:  Karine Adel-Patient; Laetitia Pothelune; Sandrine Ah-Leung; Jean-Michel Wal; Christophe Créminon; Jean-Marc Chatel
Journal:  Clin Vaccine Immunol       Date:  2009-11-18

7.  Antibacterial resistance, macrophage influx, and activation induced by bacterial rRNA with dimethyldioctadecylammonium bromide.

Authors:  R Gonggrijp; W J Mullers; H F Dullens; C P van Boven
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

8.  Muramyl dipeptide analogues as potentiators of the antitumor action of endotoxin.

Authors:  N Bloksma; F M Hofhuis; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  Treatment of acute experimental toxoplasmosis with investigational poloxamers.

Authors:  J L Krahenbuhl; Y Fukutomi; L Gu
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  Nonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondii.

Authors:  F G Araujo; T Slifer
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.